REG - Arecor Therapeutics - 2025 Business Update

Arecor TherapeuticsAnnouncement

09/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260209:nRSI1428Sa&default-theme=true

RNS Number : 1428S  Arecor Therapeutics PLC  09 February 2026

Arecor Therapeutics plc
("Arecor" or the "Company")

2025 Business Update

 

 

Cambridge, UK, 9 February 2026: Arecor Therapeutics plc (AIM: AREC), a
biopharmaceutical company focused on drug development and enhanced delivery in
diabetes and other cardiometabolic diseases, provides a business update
(unaudited) for the 12 months ended 31 December 2025. The Company's audited
results will be issued during April 2026.

Highlights

 * Continued focus on two core product areas: diabetes and oral delivery of
peptides - high growth multi-billion-dollar markets

 * Co-development deal signed in September 2025 with Sequel Med Tech ('Sequel')
to combine Arecor's ultra-concentrated, ultra-rapid-acting (500U/mL) insulin,
AT278, with Sequel's twiist™ Automated Insulin Delivery (AID) system

 * Also in September 2025, Arecor signed a non-dilutive royalty financing
agreement with Ligand Pharmaceuticals for up to $11 million cash, with $7
million received on signing

 * Total revenue for the year including discontinued operations is £3.1 million
(2024: £5.1 million) with the decrease due to the cessation of operations at
Tetris Pharma

 * Cash and cash equivalents of £6.1 million (2024: £3.2 million) above
expectations mostly due to favourable performance at Tetris

AT278

Significant development and commercial progress has been made with Arecor's
ultra-concentrated (500U/mL), ultra-rapid-acting insulin, most notably with
the US Food and Drug Administration (FDA) and through partnering with insulin
pump innovators as the preferred route to market.

In early September 2025 the Company had a positive Type C meeting with the FDA
on a first-of-a-kind Phase 2 clinical study design for AT278, in combination
with an Automated Insulin Delivery (AID) system in people with both type 1 and
type 2 diabetes with high daily insulin needs. Positive feedback and guidance
on this innovative clinical trial design was a major achievement for Arecor
and a significant step towards a successful Phase 2 study.

That same month, Arecor and Sequel, a company developing state-of-the-art
insulin delivery devices, announced a collaboration committing up to $1.3
million each to fund development work in preparation for the pivotal Phase 2
trial combining AT278 with Sequel's twiist™ AID system, which has been
launched in the US.

The collaboration was discussed recently in a fireside panel discussion with
Dr Sarah Howell (Arecor), Dr Alan Lotvin (Sequel), and Dr Thomas Blevins, a
Key Opinion Leader in the field of Diabetes and Endocrinology - see the
recording here (https://arecor.com/investor-centre/) .

Positive negotiations are in progress on a broader co-development and
commercialisation partnership for the Phase 2 trial and beyond and are a
current key focus for management.

Oral peptide delivery platform

This R&D programme is aiming to improve the bioavailability of peptides
when delivered orally. The initial focus is to develop an oral GLP-1
(semaglutide) with improved bioavailability. Rybelsus®, a current approved
oral semaglutide, has a bioavailability of <1%.

Non-clinical pharmacokinetic (PK) studies to inform the optimum approach to
improve bioavailability are underway and will be on-going through 2026. During
Q4 25, Arecor filed a patent application with the European Patent office,
claiming novel compositions to improve the oral bioavailability of complex
peptides.

Success with oral GLP-1 would be highly translatable to the oral delivery of a
broad range of peptides, offering a significant commercial opportunity.

Financials

Total revenue for the year including discontinued operations is £3.1 million
(2024: £5.1 million) with the decrease due to the cessation of operations at
Tetris Pharma.  This includes revenue for continuing operations* of £1.7
million (2024: £1.6 million). Cash and cash equivalents of £6.1 million
(2024: £3.2 million) above expectations mostly due to favourable performance
at Tetris.

* Continuing operations exclude Tetris Pharma, with the cessation of
operations in September 2025.

 

Sarah Howell, Chief Executive Officer of Arecor, said:

"During 2025, we focused our strategy on two core product areas, AT278 for
diabetes and the oral delivery of peptides, both of which are high growth
multi-billion-dollar markets where our technology gives us an edge. The
combination of AT278 with a device such as Sequel's twiist™ AID system
addresses key unmet needs for people living with diabetes and is a compelling
proposition for this growing market.

"We are also continuing to generate insights and data to inform next
development steps for our oral peptide delivery platform, which has a low
resource burden but a large commercial upside opportunity. These developments
are supported by a solid financial position."

-ENDS-

For more information, please contact:

 Arecor Therapeutics plc                     +44 (0) 1223 426060

Dr Sarah Howell, Chief Executive Officer

David Ellam, Chief Financial Officer       info@arecor.com

 Singer Capital Markets Advisory LLP         +44 (0) 20 7496 3000

(NOMAD and Broker)
 Phil Davies, Andrew Johnson, James Todd

 Vigo Consulting (Financial Communications)  +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris

                                             arecor@vigoconsulting.com

 

Notes to Editors

About Arecor

Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused
on drug development and delivery in diabetes and other cardiometabolic
diseases. The Company is applying its proprietary technology platform,
Arestat®, to develop a portfolio of proprietary products, as well as working
with leading pharmaceutical and biotechnology companies to deliver therapeutic
products. Its lead product is AT278, the only ultra-concentrated (500U/mL)
ultra-rapid acting insulin. Arecor is also developing a novel oral delivery
platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and
diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in
Cambridge, UK.  For further details please see www.arecor.com
(http://www.arecor.com) .

Arecor® and Arestat® are registered trademarks of Arecor Limited.

About AT278

AT278 is a novel proprietary formulation of an existing insulin, designed to
accelerate the absorption of insulin post injection even at very high
concentrations (500U/mL). With its best-in-class profile, it has the potential
to disrupt the market for insulin treatment as the first concentrated, yet
very rapid acting insulin for the growing population of people with diabetes
with high daily insulin needs as well as to act as a critical enabler in the
development of next-generation, miniaturised longer wear automated insulin
delivery (AID) systems.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEASAPESFKEFA



            Copyright 2019 Regulatory News Service, all rights reserved